ArticleCureus2020
Depression Among Keratoconus Patients in Saudi Arabia.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.
- Beyond Vision: Unveiling the Psychiatric Dimensions of Keratoconus.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Depression among keratoconus patients: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Sociodemographic and clinical characteristics of keratoconus: multi-centric study from India.Eye (London, England) · 2026Article
- Binocular vision disorders and refractive errors on university students' quality of life.International journal of ophthalmology · 2025Article
- Psychological and Psychiatric Characteristics of People with Keratoconus.Reports (MDPI) · 2024Article
- The Lifetime Expenditure in People with Keratoconus in Saudi Arabia.Vision (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Depression is a highly prevalent disorder globally and locally in Saudi Arabia. Individuals with chronic conditions are more liable to develop depression. Keratoconus is a chronic progressive corneal disorder that markedly affects the vision and quality of life, making its sufferers liable to developing depression. Methods This is a descriptive cross-sectional study that was conducted using 9-item Patient Health Questionnaire (PHQ-9) to screen for depression among adults aged between 18 and 60 years old only. The participants in this study are patients who have been previously diagnosed with keratoconus by their ophthalmologists. The structured questionnaire was distributed using Google Forms through various social media platforms. After extracting the data, it was revised, coded and then analyzed using the Statistical Packages for Social Sciences (SPSS), version 21 (IBM Corp., Armonk, NY). Results A total of 330 keratoconus patients living in Saudi Arabia were recruited in this study. The modal age group was 31-40 years old (44.5%), and the male to female ratio was 3:2. The most frequently reported concurrent eye diseases of the patients were astigmatism (48.5%) and myopia (36.7%). The prevalence of depression among patients with keratoconus was 40.6% (n = 134). The use of corrective contact lens (includes both: hybrid and rigid lens) in both eyes contributed to a significantly higher depression rate among its wearers compared to users in one eye and non-users (p<0.001). Conclusion Depression is highly prevalent among keratoconus patients. This is especially true among corrective contact lens wearers of both eyes. Keratoconus is associated with depression regardless of disease severity and socio-demographic characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.